As we have previously reported, thousands of lawsuits have been filed against Takeda Pharmaceutical Company for its medication Actos after studies revealed that diabetics taking the drug may be at an increased risk of developing bladder cancer. In 2011, the U.S. Food and Drug Administration (FDA) warned that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.

A plaintiff, alleging Actos caused his bladder cancer, was recently awarded $2.3 million in compensatory damages by a jury in Pennsylvania state court. The jury found that Takeda showed “reckless indifference” to the plaintiff’s health by hiding Actos’ risks and awarded another $1.3 million in punitive damages. There are approximately 8,000 other similar lawsuits currently pending in federal and state courts across the country.

If you believe you have experienced adverse side-effects from taking Actos, contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of Actos.

The Honorable Rebecca F. Doherty, who is overseeing the federal Actos cases centralized in Louisiana, has appointed 19 plaintiffs’ attorneys to manage the litigation. As we have previously reported, recent studies allegedly show that diabetics taking Actos may be at an increased risk of developing bladder cancer. A recent Bloomberg article stated that Takeda Pharmaceutical Company, the Asian-based manufacturer of Actos, could face upwards of 10,000 lawsuits in the United States. Eli Lilly & Company, which is also currently involved in the Darvocet litigation, has been named as a co-defendant based on allegations that the company withheld information from consumers about the associated risks and failed to provide adequate label warnings.

According to a March 12, 2012 note posted on the Court’s website,  Judge Doherty advised that“[t]he Court has determined to effect the selection of lead counsel, liaison counsel, and plaintiffs’ executive and steering committees before the March 22nd- 23rd status conference.” The selection will allow for the plaintiffs’ attorneys to meet and confer while in Lafayette for the initial March conference.

If you feel you have experienced adverse side-effects from taking Actos, contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of Actos.

The United States Judicial Panel on Multi-District Litigation (MDL) met on December 1, 2011, in Savannah, Georgia, to hear arguments regarding whether all federal Actos cases should be consolidated into multi-district litigation (MDL) and, if so, where the cases should be consolidated.

As we have previously reported, recent studies allegedly show that diabetics taking Actos may be at an increased risk of developing bladder cancer.  Particularly at risk are those individuals who took Actos for more than twelve (12) months.

On December 29, 2011, the Panel decided that all federal Actos cases would be centralized in the Western District of Louisiana with the Honorable Rebecca F. Doherty.  The granting of multi-district litigation (MDL) treatment will streamline the lawsuits, allowing the parties to avoid duplicative discovery and inconsistent rulings from different judges.  Additionally, MDL treatment will provide more convenience for the witnesses, the parties and the court.

If you feel you have experienced adverse side-effects from taking Actos, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of Actos.

The United States Judicial Panel on Multi-District Litigation (JPML) met on Thursday, December 1, 2011, in Savannah, Georgia, to hear arguments regarding whether all federal Actos cases should be consolidated into multi-district (MDL). Recent studies allegedly show that diabetics taking Actos may be at an increased risk of developing bladder cancer. The JPML has yet to issue a ruling, but a decision is expected early next year. Considering that the attorneys for manufacturer, Takeda Pharmaceuticals, have recently agreed that the cases should be consolidated, it would come as a surprise if the JPML denied Plaintiff’s motion.

The real question for the JPML is where to centralize the cases. The filing Plaintiff requested that the cases be consolidated in the Southern District of Illinois before Judge G. Patrick Murphy, while Takeda Pharmaceuticals has requested that the cases be consolidated in either the Northern District of Illinois or the Western District of Louisiana.

As we have previously discussed, granting MDL treatment will consolidate all federal Actos lawsuits filed across the U.S. into one centralized district. This consolidation will streamline the pretrial discovery process, allowing the parties to avoid duplicative discovery and inconsistent rulings from different judges.

If you feel you have experienced adverse side-effects from taking Actos, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of Actos.

The United States Judicial Panel on Multi-District Litigation (MDL) is scheduled to meet on December 1, 2011, in Savannah, Georgia to hear arguments on whether all federal Actos cases should be centralized, pursuant to 28 U.S.C.§ 1407, for coordinated or consolidated pretrial proceedings, and if so, which federal district is the appropriate forum for these proceedings.  As we have previously advised, new studies show that diabetics taking Actos may be at an increased risk of developing bladder cancer.

A motion was initially filed by a plaintiff in August 2011, requesting that all Actos lawsuits filed in the various federal district courts throughout the United States be centralized in the U.S. District Court for the Southern District of Illinois before Judge G. Patrick Murphy.  Currently, more than a dozen lawsuits have already been filed against the manufacturers of Actos with hundreds more expected in the near future.

Just recently, the attorneys for manufacturer, Takeda Pharmaceuticals, filed a response with the United States Judicial Panel on Multi-District Litigation, advising that they agree with plaintiffs that an MDL should be formed, but requested that the cases be consolidated in either the Northern District of Illinois or the Western District of Louisiana.

Granting MDL treatment will streamline the lawsuits, allowing the parties to avoid duplicative discovery and inconsistent rulings from different judges.  Additionally, MDL treatment will provide more convenience for the witnesses, the parties and the court.  During the pretrial litigation, the MDL judge will manage discovery and likely select a group of cases for early trials, also known as bellwether cases.

If you feel you have experienced adverse side-effects from taking Actos, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of Actos.

A class action was filed in September 2011 against Takeda Pharmaceuticals and Eli Lilly, the manufacturers of the diabetic drug, Actos.  The lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana on behalf of two individuals who developed bladder cancer after taking Actos. The complaint also seeks class certification to include coverage for the millions of individuals who used Actos in the United States since it was marketed in 1999.

If you feel you have experienced adverse side-effects from taking Actos, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of Actos.

As of August 2011, Actos (Pioglitazone), manufactured by Takeda Pharmaceuticals, was the best selling Type 2 diabetes drug in the world. Introduced to the U.S. market in July 1999, the popularity of the drug has steadily increased over the years, generating over $4 billion in sales in 2010.  However, in June 2011, a study of more than 1 million diabetics was commissioned by the French government. The study, consisting of approximately 155,000 on Actos and 1.3 million on other medications, found that Actos patients demonstrated nearly a 22 percent higher risk of bladder cancer when compared to those taking other medications. Additionally, the risk of bladder cancer was highest in those individuals receiving a cumulative Actos dosage of 28,000 mg or more during the study period.  Immediately following this study, sales of Actos were suspended in France and Germany, while the FDA issued new bladder cancer warnings for individuals taking Actos in excess of one year.

Another study, based on data obtained from the Kaiser Permanente Northern California Health Plan, found that diabetics over 40 years old who had taken Actos for longer than 12 months had a 40% increased risk of bladder cancer when compared with patients who had never taken the drug.

Notwithstanding the FDA’s very recent decision, many are alleging that Takeda Pharmaceuticals did not provide proper notice of the risk of bladder cancer to potential users of the drug.

If you feel you have experienced adverse side-effects from taking Actos, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturers of Actos.